Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5870_Библиотеки_им_академика_М_И_Перельмана
.pdf
GLOSSARY OF TERMS
https://t.me/medicina_free
SHATTER - translucent cannabis concentrate, created by extracting the cannabinoids and terpenes,
with a specific texture that breaks and shatters like glass.
STRAIN - a term used interchangeably with “variety” and “selection” in the cannabis industry. It has
no official botanical meaning. In the world of cannabis, the term refers to the flower’s particular
variety, be it Sour Diesel, or Jack Herer.
TERPENES - volatile hydrocarbons found in the essential oils produced by many plants,
including cannabis.
herbal spice.
TETRAHYDROCANNABINOL (THC) or DELTA-9 THC - the principle phytocannabinoid of the
cannabis plant, responsible for much of the plant’s psychoactivity.
TETRAHYDROCANNBINOLIC ACID (THCA) - the most common cannabinoid found in the raw
cannabis plant. THCA is non-intoxicating but converts into the intoxicating THC when exposed to heat
through a process called decarboxylation.
TETRAHYDROCANNABIVARINIC (THCV) - a homologue of tetrahydrocannabinol (THC) having a
propyl (3-carbon) side chain instead of the pentyl (5-carbon) group on the molecule, which makes it
produce very different effects from THC.
TINCTURE - a solution of a medicinal substance in an alcoholic solvent.
TOLERANCE - an individual’s reaction to the dose of cannabis in which the effects are progressively
reduced, requiring an increase in the dosage in order to achieve the desired therapeutic effect.
TOPICAL - a lotion, ointment, oil, or transdermal patch that is applied directly to the body’s skin
surface. Topics allow patients to enjoy the plant’s therapeutic effects without THC’s attendant
psychoactivity.
232
GLOSSARY OF TERMS
https://t.me/medicina_free
TRICHOME - “ball - like” clear “globes” on the surface of the cannabis flower that produce and hold
the plant’s cannabinoids and terpenes. Trichomes have a sugary, crystal-like appearance.
VAPE - the process of inhaling and exhaling vapor with the use of a vaporizer, dab rig, or similar
device. These devices utilize a heating element to quickly vaporize the active ingredients in cannabis
for smooth, non-combusting consumption.
VAPE PEN OR VAPORIZOR - a handheld device consisting of a battery attached to a cartridge
filled with cannabis concentrate. With a Vape Pen, concentrates are heated not burned. Instead of
smoke, the output is vapor.
WAX - cannabis concentrate of cannabinoids and terpenes that contains some of the waxy coverings
that contain the oils on the plant, which gives a opaque and crumbly texture.
WILKINSON MEMO - issued in October 2014; provides that eight enumerated federal priorities
“will guide United States Attorneys’ marijuana enforcement efforts in Indian Country,” including where
“sovereign Indian Nations seek to legalize the cultivation or use of marijuana in Indian Country”.
233
https://t.me/medicina_free
INDEX
https://t.me/medicina_free
Abortion medications, migraines and, 164
Addiction, 170
cannabis and, 212
opioids and, 188
rate, cannabis and, 205
withdrawal, 190
withdrawal, clinical opiate withdrawal scale, 190
Adolescents
Dronabinol and, 76
oral solution (Syndros®) and, 79
Nabilone (Cesament®) and, 77
Nabiximols (Sativex®) and, 82
Adverse side effects, pain and, 170
AED. See Antiepileptic drugs.
Affirmative defense, 7
Alcohol, Nabiximols (Sativex®) and, 82
ALS. See Amyotrophic Lateral Sclerosis.
Alzheimer’s disease, 166, 167
Amyotrophic Lateral Sclerosis (ALS), 166, 167
Anadamide, 30, 40
medical trials, 34
Anslinger, Harry, 19
Anti-inflammatories, 42
treatment of, 152
Antibacterial properties, CBD and, 125
Antidepressants, 146
Antiepileptic drugs (AED), 154
resistance to, 154
Antioxidants, 31
Anxiety disorders, 146–149
proposed mechanism, endocannabinoid systems, 148
treatment of, antidepressants, 146
benzodiazepines, 146
cannabidiol, 147
cognitive behavioral therapy, 146
selective serotonin reuptake inhibitors, 147
THC and CBD, 148
Anxiolytic effect, 152
Appetite stimulant, 78
Arcview Market Research, 4
Arizona, decriminalization of medical marijuana, 8
Arthritis, 170
Aspirin, 19
Bayer Co, 19
Attorney General Eric Holder, 4
Avyurvedic medicine, 16
Banking regulations
Financial Crimes Enforcement Network, 7
money laundering statutes, 7
Barbiturates, 19
Bayer Aspirin, 19
Benzodiazepines, 146
BHO (Butane Hash Oil), 90
Biphasic effect, dosing and, 126
Bloodstream absorption via medicating type, 115
Bong design, 98–99
Botanical compounds, single molecule compounds
vs., 68
Brain
cell loss, cannabis and, 213
receptors in, 41
Breast milk, 76, 79, 80, 82
Budder, 90
Budtenders, state laws and, 87
Butane Hash Oil. See BHO.
California, medical marijuana decriminalization, 8
California Proposition Act 215,
Compassionate Care Act, 24
Cancer, 150–153
Common treatments, 150
Cancer cannabinoid therapeutics, 150
chemotherapy after-effects, 150
clinical trials, 150
dosage size, 151
FDA approval
dronabinol, 151
nabilone, 151
235
Cancer cannabinoid therapeutics (cont.)
https://t.me/medicina_free
proposed mechanism, 152
anti-inflammatory effect, 152
anxiolytic effect, 152
inhibitor to, 152
orexigenic effect, 152
Cannabichromenic acid (CBC), 56, 57
Cannabidiol (Epidiolex®), 75, 79
abuse of, 80
adverse effects, 80
breast milk, 80
dependency, 80
Dravet syndrome, 80
fetus, 80
infantile spasm, 80
Lennox-Gastaut syndrome, 80
oromucosal, 80
Orphan Drug designation, 80
Rare Pediatric Disease designation, 80
Schedule V classification, 80
tuberous sclerosis, 80
Cannabidiol cannabinoid, 4
Cannabidiol Nabiximols, 81–82
Cannabidiol, 29, 43, 55
antibacterial properties, 125
anxiety disorders and, 148
CBD to THC ratio, 81, 129
dosing and, 121
chemical mimics of, 30
extract research, 80
adverse effects, 80
therapeutic effects, 80
treatment results, 80
immunocompromised patients, dosing and, 125
seasonal affective disorder, 147
sleep disorders in, 161
THC interaction with, 127
2-AG, 30
Cannabidiol, uses of, 55
Cannabigerol (CBG), 56
Cannabinoid Hyperemesis Syndrome (CHS), 201
Cannabinoid receptors, newborn development of, 48
Cannabinoid testing, composition of, 139–140
chromatography, 139
composition of,
contaminants, 139
potency, 139–140
requirements, 140
standards, 140
terpene, 139
THC total, 140
Cannabinoid therapeutics, 150
clinical trials, dosage size, 151
epilepsy, 154–155
children, 155
enhancements to treatment, 154
proposed mechanism, 155
purified CBD, 154
gastrointestinal disorders, 156–159
proposed mechanism, 158
remission of, 158
migraine headaches, 164–165
neurodegenerative disorders, 166–169
disorders
clinical trials, 168
proposed mechanism, 168
pain, 170–171
proposed mechanisms, 171
post traumatic stress disorder, 172–173
dosage concerns, 173
mental family history, 173
proposed mechanism, 173
THC dosage, 173
sleep disorders, 160–163
CBD in, 161
CBN in, 161
encannabinoid signaling, 162
proposed mechanism, 162
short vs. long term use, 160
terpenes in, 161
THC in, 161
Cannabinoids, dispensing of, 87
budtenders, 87
concentrates, 90–92
flower vs. concentrates, 88–89
Medical Marijuana 411, 87
Federal Farm Bill of 2018, 83
Cannabinoids, future of, 82–83
236
cannabis sativa extracts, 83
https://t.me/medicina_free
Cannabinoids, isolating individual components, 64
Marinol®, 64
Cannabinoids, major types, 55
cannabidiol, 55
tetrahydrocannabinol, 55
Cannabinoids
medications, 75
minor, 56
purified, 154
receptor interaction with, 41
summary listing, 174
terpenes and, entourage effect, 64
Cannabinol (CBN), 43, 56
sleep disorders in, 161
Cannabis indica, 3
Cannabis ruderalis, 3
Cannabis sativa extracts, 83
isolate vs. whole plant dosing curve, 83
Cannabis sativa L., 3
Cannabis
abuse of, 204–205
addiction rates, 205
Cannabinoid Hyperemesis Syndrome, 204
marijuana use disorder, 205
pediatric exposure, 204
symptoms of, 205
unintentional, 204
archeological evidence of use, 16
bi-products,
manufacturing
dosage issues, 18
tincture manufacturing, 18
Cannabis indica, 3
Cannabis ruderalis, 3
Cannabis sativa L., 3
Catholic Church, 18
chemistry of, 29
cannabidiol, 29
Howlett, Allyn, 29
LD50, 30
Mechoulam, Raphael, 29
THC, 29
classification of, 68
decriminalization of, 3
dosing, THC and, 124
driving a vehicle and, 203
drug classification of, 3
early history of, 15–18
Caucasus Mountains, 15
Indica varieties, 15
Sativa varieties, 15
Silk Route, 15
European view of, 18
FDA oversight, 83
incorrect labeling, 83
Latin America and, 18
legal sales of, 4
medical benefits, 3
medical use summary, 175
medicating forms, 96–114
medicinal prescriptions for 19
medicine, 24
ancient Chinese use, 16
Egyptian use, 16
England, 18
Queen Victoria’s impact on, 18
The Lancet, 18
Greek use, 16
hemp oils, 18
Indian Ayurvedic medicine, 16
making and selling, 18
Russia, 16
United States, 18
migraine headaches,
clinical trials, 164
proposed mechanism, 165
withdrawal symptoms, and 165
motor vehicle operation, 203
narcotic classification, 19
neurodegenerative disorders and, 166
newborns, 48
Jamaican study of, 48
oil derived from 16
healer’s use of, 16
opioids vs., 190
impact of 190
withdrawal mitigation, 68
237
Cannabis (cont.)
https://t.me/medicina_free
overdose deaths, 29
pain and, 170–171
adverse side effects, 170
arthritis, 170
clinical trials, 170
dosages, 171
drug-drug interactions, 171
myofascial pain, 170
nabiximols, 170
pain management and,
effectiveness of, 190
withdrawal symptoms, 190
patents on, 31
possession, affirmative defense, 7
post traumatic stress disorder and, 172–173
clinical trials, 172–173
nabilone, 172–173
recreational drug use, 3
Marihuana Tax Act of 1937 effect on, 19
Schedule 1 drug, 31
controlled substance, 5
side effects, 199–200
breathing problems, 200
child development, 201
heart rate, 201
in utero, 201
leukoedema, 202
lung cancer, 200
male sexual dysfunction, 202
mental issues, 202
miscellaneous, 203
nausea, 201
oral mucosa irritation, 202
physical effects, 200
sleep disturbance, 202
stroke, 201
xerostomia, 202
states and, 5
tolerance of, 65
truth or fiction
addictive qualities, 212
brain cell loss, 213
concentration ability, 215
gateway drug, 211
lung cancer, 216
memory impairment, 215
mental illness, 216
motivational qualities of, 214
perceived dangers of, 219
recreational use, 218
withdrawal symptoms, 212
United States Pharmacopeia, removal from, 19
United States Prohibition effect on, 20
western religion’s effect on, 18
western view of, 18
Spanish Conquistadors, 18
Cardiac patients, dosing of, 124
Catholic Church, 18
CB1 receptors, 33, 40, 42
anti-inflammatories, 42
brain, 41
glial cells, 41
psychoactive effects, 42
CB2 receptors, 33, 41, 42
cytokine release, 41
CBC. See cannabichromenic acid.
CBD. See cannabidiol.
CBG. See cannabigerol.
CBN. See cannabinol.
CBT. See cognitive behavioral therapy.
CDAI. See Crohn’s Disease Activity Index.
Cesamet®, 77
Chemotherapy, 76, 77
after-effects, cannabis and, 150
Chemotherapy-induced nausea, 77, 79
Children
cannabinoid treatment and epilepsy, 155
FDA approval, 155
development of, cannabis and, 201
Dronabinol and, 76
Dronabinol oral solution (Syndros®) and, 79
Nabilone (Cesament®) and, 77
Nabiximols (Sativex®) and, 82
Chinese medicine, use of cannabis, 16
Shen Nung, 16
Chromatography, 139
high pressure liquid chromatography, 139
238
CHS. See Cannabinoid Hyperemesis Syndrome.
https://t.me/medicina_free
Clinical opiate withdrawal scale (COWS), 190
Clinical review
anxiety disorders, 146–149
cancer, 150–153
Cognitive behavioral therapy (CBT), 146
Cole Memo, 4, 6
Conant v. Walters, 7
Department of Justice, 6
healthcare professionals and, 7–8
Compassionate Care Act, 24
Conant v. Walters, 7–8
affirmative defense, 7
impact on healthcare professionals, 8–9
physician license revocation, 8–9
Concentrates, cannabinoids and, 90–92
budder, 90
dabbing, 90, 95
disadvantages of, 92
extraction methods, 92–93
forms of, 90
BHO, 90
medicating formats, 96–114
rosin, 92
shatter, 90
vaporization, 90
wax, 90
Concentration ability, cannabis and, 215
Conduction vaporizers, 100
Contaminant testing, 139, 140
fungal diseases, 139
pesticides, 139
Controlled Substance Act, 5, 20
cannabis as Schedule 1 classification, 20
DEA and, 20
Controlled substances, Federal Government
listing, 5
Convection vaporizers, 100
Couchlock, 15
COWS. See clinical opiate withdrawal scale.
Crohn’s Disease Activity Index (CDAI), 157
Cytokines, release of, 41
Dabbing, 90, 95
DEA. See U.S. Drug Enforcement Agency.
Decriminalization of medical marijuana, 8
Arizona, 8
California, 8
prescription for, 8
Shafer Commission and, 20
Delta-9 tetrahydrocannabinol. See THC.
Department of Justice, Cole Memo, 6
Dopamine, 65
Dosing curve, 83
Dosing, 121–131
biphasic effect, 126
cannabis and pain, 171
cannabis bi-products and, 18
CBD interaction with THC, 127
CBD vs. THC ratio, 121
drug interactions, 122
NIDA studies and, 124
ratio protocol of, 128, 129
edibles, 130
inhalation, 130
specific illnesses, 130
tinctures, 130
topicals, 131
relative contraindications, 123–125
risk of dysphoria, 122
set and setting, 122
self-titration, 121
size, cannabinoid therapeutic clinical trials and, 151
THC sensitivity, 121
tincture,19
titration, edible format and, 104
Dravet syndrome, 80, 154, 155
Dreher, Melanie, Dr. 48
Dronabinol (Marinol®), 75, 151
Dronabinol oral solution (Syndros®), 75–76
adolescents, 76, 79
adverse effects, 76, 79
appetite stimulant, 78
breast milk, 76, 79
chemotherapy, 76
nausea from, 79
239
Dronabinol oral solution (Syndros®) (cont.)
https://t.me/medicina_free
children, 76, 79
fetus, 76, 79
HIV associated cachexia, 76
oromucosal, 79
overdose, 76
physician supervision, 76
Schedule III, 76
variability between patients, 78
Drug Classification Schedule., 3, 22–23
Drug interactions, dosing and, 122
Drug-drug interactions, 122, 171
Marinol®, 122
Sativex®, 122
Dymenorrea, 18
Dysphoria risk, dosing and, 122
ECS. See endocannabinoid system.
Edibles, 104–107, 130
do’s and don’ts, 106–107
dose titration, 104
forms of, 104
Egyptian medicine, use of cannabis, 16
Eidolex®. See Cannabidiol.
Elderly patients, Nabiximols (Sativex®) and, 82
Eli Lilly Corp., 18
Employment law, 7
Endocannabinoid receptors, 30
Endocannabinoid system (ECS), 31–35, 39–42, 148
antioxidants, 31
anadamide, 34
Cannabidiol, 43
CB1 receptors, 33, 42
CB2 receptors, 33, 42
forgetting and, 44
homeostasis, 31, 40
hyperactivity, 44
injury reaction by, 31
medical profession bias, 34
nerve synapse, 39
neuron communication, 39
neuroprotectants, 31
newborn development, 48
Omega-3 fatty acids,
pain, 45
Post Traumatic Stress Disorder, 45
receptors, 39
retrograde inhibition, 44
Tetrahydrocannabinol, 43
traumatic brain injury, 44
glutamate toxicity reduction, 44
neuronal damage reduction, 44
2-AG, 42
unforeseen consequences, 44
tolerance of, 65
types
anadamide, 40
receptors, 40
2-AG, 40
England, cannabis medicine, 18
Entourage effect, 64
Epidiolex®. See Cannabidiol.
Epilepsy, 154–155
cannabinoid therapeutics, 154–155
children, 155
enhancements, 154
common treatments, 154
antiepliptic drugs, 154
resistance to, 154
Europe, 18
Sir William Brook O’Shaughnessy, 18
Extraction methods in concentrates, 92–93
hydrocarbon, 92
Farm Bill, industrial hemp, legalization of, 3
Fasting, 77
FDA. See Food and Drug Administation.
Federal government cannabis control
banking regulations, 7
bankruptcy protection, 7
Cole Memo, 6
employment law, 7
Ogden Memo, 6
Rohrabacher-Farr Amendment, 6
tax deductions, 6
taxes, 6
240
Federal Farm Bill of 2018, 83
https://t.me/medicina_free
Federal Government legal overview, 3–6
Federal protection of trademarks, 5
Fetus, 76, 79, 80, 82, 123
Financial Crimes Enforcement Network (FinCEN), 4, 7
FinCEN. See Financial Crimes Enforcement Network.
Flowers, cannabinoids and, 88–89
Food and Drug Administration (FDA),
approval cannabinoids, 151
dronabinol, 151
nabilone, 151
epileptic treatment for children, 155
cannabis and, 83
Fride, Ester, 48
Fungal diseases, 139
mildew, 139
molds, 139
marijuana vs. 3
THC level of, 3
Heroin, 65
High pressure liquid chromatography (HPLC), 139
High-THC cannabinoid therapy, youths under 25
and, 124
high CBD: low THC, 124
studies on, 124
NIDA, 124
Holder, Eric, 4
cannabis legalization, 4
Homeostasis, 31, 40
Howlet, Allyn, 29
HPLC. See high pressure liquid chromatography.
Huntington’s disease, 167
Hydrocarbon extraction, 92
Hyperactivity, 44
Gallup Poll, legalization and, 4
Gastroesphageal reflux disease (GERD), 158
Gastrointestinal disorders (GI), 156–159
Cannabinoid treatment, 156–157
trials, 157
Crohn’s Disease Activity Index, 157
gastroesphageal reflux disease, 158
irritable bowel disease, 156–157
nonsteroidal anti-inflammatory drug and, 193
Gateway drug, cannabis as, 211
GERD. See gastroesphageal reflux disease.
GI. See gastrointestinal disorders.
Glial cells, 41
Glutamate toxicity reduction, 44
Greek medicine, use of cannabis, 16
Healthcare professionals
cannabis discussions do’s and don’ts, 8–9
legality of cannabis discussions with patients, 8–9
Heart rate, cannabis and, 201
Hemp
oils, 18
Federal Farm Bill of 2018 and, 83
industrial, 3
IBD. See irritable bowel disease.
Immunocompromised patients, dosing and, 125
CBD, 125
inhaled mold, 125
invasive aspergillosis, 125
dosing and, THC, 125
India medicine, 18
hemp oils, 18
Sir William Brook O’Shaughnessy, 18
Indian Ayurvedic medicine, 16
Indica plant, 15
couchlock, 15
phychoactive results, 15
Industrial hemp, 3
legalization of, 3
Marihuana Tax Act effect on, 19
medical cannabis vs., 24
Infantile spasm (IS), 80
Inhalation of cannabis, 96–99, 130
bong design, 98–99
vaporizers, 100–103
Inhaled mold, 125
Injury, endocannabinoid system reaction and, 31
Internal Revenue Service, implications from Marihuana
Tax Act of 1937, 19
241
Соседние файлы в папке Библиотека им академика М.И. Перельмана